GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OKYO Pharma Ltd (NAS:OKYO) » Definitions » Shares Outstanding (Diluted Average)

OKYO Pharma (OKYO Pharma) Shares Outstanding (Diluted Average) : 51.04 Mil (As of Mar. 2023)


View and export this data going back to 2022. Start your Free Trial

What is OKYO Pharma Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. OKYO Pharma's average diluted shares outstanding for the quarter that ended in Mar. 2023 was 51.04 Mil.


OKYO Pharma Shares Outstanding (Diluted Average) Historical Data

The historical data trend for OKYO Pharma's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OKYO Pharma Shares Outstanding (Diluted Average) Chart

OKYO Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Shares Outstanding (Diluted Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 513.90 595.47 10.35 798.26 22.26

OKYO Pharma Semi-Annual Data
Sep13 Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23
Shares Outstanding (Diluted Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.35 910.47 21.15 1,406.83 51.04

OKYO Pharma Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


OKYO Pharma  (NAS:OKYO) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


OKYO Pharma Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of OKYO Pharma's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


OKYO Pharma (OKYO Pharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OKYO Pharma Ltd (NAS:OKYO) » Definitions » Shares Outstanding (Diluted Average)
Traded in Other Exchanges
Address
14/15 Conduit St, Floor 4, London, GBR, W1S 2XJ
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
Executives
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob director, officer: Chief Executive Officer
Gabriele M Cerrone director, 10 percent owner, officer: Executive Chairman 265 EAST 66TH STREET, SUITE 16G, NEW YORK NY 10021
Bernard Denoyer director C/O CALLISTO PHARMACEUTICALS, INC., 420 LEXINGTON AVENUE, SUITE 1609, NEW YORK NY 10170
Willy Jules Simon director PLAYLOGIC INTERNATIONAL NV, CONCERTGEBOUWPLEIN 13, AMSTERDAM P7 1071 LL
Keeren Shah officer: Chief Financial Officer 55 PARK LANE, LONDON X0 W1K 1NA

OKYO Pharma (OKYO Pharma) Headlines